The new extended-cycle levonorgestrel-ethinyl estradiol oral contraceptives
- PMID: 24453511
- PMCID: PMC3888068
- DOI: 10.4137/CMRH.S5030
The new extended-cycle levonorgestrel-ethinyl estradiol oral contraceptives
Abstract
Effective contraceptive counseling requires an understanding of a woman's preferences and medical history as well as the risks, benefits, side effects, and contraindications of each contraceptive method. Hormonal contraceptives using a variety of delivery methods are highly effective and this review highlights the new extended-cycle levonorgestrel-ethinyl estradiol contraceptives. Extended-cycle OCPs are unique in offering fewer or no withdrawal bleeds over the course of one year but providers need to carefully counsel women regarding the initial increased breakthrough bleeding. Extended-cycle OCPs may be of particular benefit in women with medical comorbidities who would benefit from less withdrawal bleeds, those desiring to avoid monthly menses due to increased hormonal withdrawal symptoms, or simply women who don't desire a monthly period. The risks associated with all extended-cycle OCPs have been found to be similar to those of traditional OCPs therefore counseling on the risks and side effects is comparable to that of any combined hormonal contraceptives. Newer extended-cycle regimens shorten or eliminate the hormone-free interval, decrease frequency of menses to four times per year or eliminate menses altogether. This can reduce the risk of common menstrual symptoms, endometriosis, or severe dysmenorrhea by offering potentially greater ovarian suppression and preventing endogenous estradiol production while still providing highly effective, rapidly reversible, and safe contraception.
Keywords: contraceptive; extended cycle; levonorgestrel.
References
-
- Krishnan S, Kiley J. The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg. International Journal of Women’s Health. 2010;2:235–9. - PMC - PubMed
-
- Schlaff WD, Lynch AM, Hughes HD, et al. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol. 2004;190:943–51. - PubMed
-
- Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–6. - PubMed
-
- Coffee A, Kuehl TK, Willis SA, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195:1311–9. - PubMed
-
- Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77(3):162–70. - PubMed
Publication types
LinkOut - more resources
Full Text Sources